Clinical Course of Arrhythmogenic Right Ventricular Cardiomyopathy in the Era of Implantable Cardioverter-Defibrillators and Radiofrequency Catheter Ablation
| Autor: | Akihiko Nogami, Susumu Adachi, Mitsuhiro Nishizaki, Kenzo Hirao, Jun-ichi Suzuki, Masatoshi Komura, Atsushi Takahashi, Mitsuaki Isobe, Junichi Nitta, Tohru Obayashi, Kenichiro Otomo, Hitoshi Hachiya, Yasuhiro Satoh, Kaoru Okishige |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Tachycardia medicine.medical_specialty Adolescent medicine.medical_treatment Catheter ablation Ventricular tachycardia Right ventricular cardiomyopathy Sudden cardiac death Young Adult Internal medicine medicine Humans Arrhythmogenic Right Ventricular Dysplasia Aged Retrospective Studies Heart Failure business.industry General Medicine Myocardial Disorder Middle Aged Implantable cardioverter-defibrillator medicine.disease Defibrillators Implantable Treatment Outcome Heart failure Catheter Ablation Tachycardia Ventricular Cardiology Female medicine.symptom Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
| Zdroj: | International Heart Journal. 51:34-40 |
| ISSN: | 1349-3299 1349-2365 |
| DOI: | 10.1536/ihj.51.34 |
| Popis: | This study investigated the clinical course of arrhythmogenic right ventricular cardiomyopathy (ARVC) patients and in particular evaluated the contribution of radiofrequency catheter ablation (RFCA) and an implantable cardioverter-defibrillator (ICD) to the treatment of ARVC. ARVC is a myocardial disorder and a cause of sudden cardiac death due to ventricular tachycardia (VT). Little is known about its prognosis in Japanese ARVC patients. Thirty-five ARVC patients were studied. Mean age of patients whose onset of ARVC was congestive heart failure (CHF) (66.0 +/- 4.0 years) was significantly higher than those whose onset was VT (44.5 +/- 14.8 years, P < 0.05). ARVC patients with CHF onset showed significantly higher death rates compared to those with VT onset. ICD treatment significantly reduced episodes of hospitalization due to VT (0.1 +/- 0.4 episodes) in comparison to treatment by RFCA (1.7 +/- 2.2 episodes, P < 0.03). RFCA treatment did not reduce recurrence of VT in the follow-up period. ICD therapy showed comparable mortality to RFCA treatment. The prognosis of ARVC with CHF onset is poor. ICD therapy significantly reduced hospitalization due to VT compared with RFCA treatment. ICD implantation in combination with medication may be a better treatment for ARVC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|